Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2010-10-06
2011-12-27
Belyavskyi, Michail (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S343100
Reexamination Certificate
active
08084253
ABSTRACT:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.
REFERENCES:
patent: 5614611 (1997-03-01), Chang
patent: 5645837 (1997-07-01), Jameson et al.
patent: 5734023 (1998-03-01), Nag et al.
patent: 5827737 (1998-10-01), Peterson et al.
patent: 5994523 (1999-11-01), Kawakami et al.
patent: 6228621 (2001-05-01), Williams et al.
patent: 0814838 (2003-05-01), None
patent: WO 9402156 (1994-02-01), None
patent: WO 0023053 (2000-04-01), None
patent: WO 0025722 (2000-05-01), None
Aarnoudse et al. Int. J Cancer, 2002, vol. 99, pp. 7-13.
Albert et al., “Dendritic Cells Acquire Antigen from Apoptotic Cells and Induce Class I-Restricted CTLs”, Nature, 1998, 392: pp. 86-89.
Alderson, M.R., et al. “Interleukin 7 Enhances Cytolytic T Lymphocyte Generation and Induces Lymphokine-activated Killer Cells from Human Peripheral Blood”, 1990. J. Exp. Med. 172: pp. 577-587.
Alters et al. “Immunotherapy of Cncer: Generation of CEA Specific CTL Using CEA Peptide Pulsed Dendritic Cells”, Dendritic Cells in Fundamental and Clinical Immunology, vol. 417, pp. 519-524, 1997.
Angelichio et al, “Comparison of Several Promoters and Polyadenylation Signals for Use in Heterologous Gene Expression in CulturedDrosophiliaCells”, Nucleic. Acids Research, vol. 19, No. 18, pp. 5037-5043, 1991.
Bakker, et al., “Melanocyte Lineage-Specific Antigen gp100 is Recognized by Melanoma-derived Tumor-infiltrating Lymphocytes”, J. of Experimental Medicine, vol. 179, Mar. 1994, pp. 1005-1009.
Bellone et al, “In Vitro Priming of Cytotoxic T Lymphocytes against Poorly Immunogenic Epitopes by Engineered antigen-presenting Cells”, Eur. J. Immunology 24: pp. 2691-2698, 1994.
Cai, et al, “Influence of Antigen Dose and Costimulation on the Primary Response of CD8+ T Cells in Vitro,” J. Exp. Med. 1996, 183, pp. 2247-2257.
Cai et al “Probing the activation requirements for naïve CD8+ T cells withDrosophiliaCell Transfectants as Antigen Presenting Cells,” Immunological Reviews, 1998, 165, pp. 249-265.
Cai et al., “Requirements for Peptide-Induced T Cell Receptor Down-regulation on Naïve CD8+ T Cells”, J. Exp. Med, vol. 185, No. 4, Feb. 17, 1997 pp. 641-651.
Cai, et al, “TransfectedDrosophilaCells as a Probe for Defining the Minimal Requirements for Stimulating Unprimed CD8+ T Cells”, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 14736-14741, Dec. 1996.
Chen et al., “Costimulation of T Cells for Tumor Immunity”, Imm. Today vol., 14, No. 10:1993 pp. 483-485.
De Wall Malefyt et al., “CD2/LFA-3 or LFA-1/1CAM-1 but not CD28/B7 Interactions can Augment Cytotoxicity by Virus-Specific CD8+ Cytotoxic T Lymphocytes”, Eur. J. Immunol. 1993, 23: pp. 418-424.
Flesch et al. “Monocyte Inflammatory Protein-1 Alpha Facilities Priming of CD8+ Cell Responses to Exogenous Viral Antigen”, Int. Immunol., vol. 12, No. 9, pp. 1365-1370, 2000.
Gagliardi, et al, “Presentation of Peptides by Cultured Monocytes or Activated T Cells Allows Specific Priming of Human Cytotoxic T Lymphocytes in vitro,” Int. Immunol. 1995, 7(11), pp. 1741-1752.
Godeau, F., et al, “Expression of a Mouse Class I MHC Molecule in Insect Cells Using a Baculovirus Vector”, Journal of Cell Biology, 1070: Abstract # 2092, 1988.
Goldsby et al. Immunology, 5thEdition, Freeman and Company, NY 2003, pp. 9-21 and pp. 362-365.
Grewal et al. “CD40 and CD154 in Cell-Mediated Immunity”, Annual Reviews in Immunology, vol. 16, 1998, pp. 111-135.
Guelly et al,“Activation Requirements of Circulating Antigen-Specific Human CD8+ Memory T Cells Probed with Insect Cell-based Artificial Antigen-Presenting Cells”, Eur. J. Immunol. 2002, 32: pp. 182-192.
Ho, et al, “Adoptive Therapy with CD8+ T Cells: It May Get by with a Little Help from its Friends”, J. of Clinical Investigation, Nov. 2002, vol. 110: No. 10, pp. 1415-1417.
Hortsch, et al., “Sticky Molecules in Not-So-Sticky Cells”, TIBS 16, Aug. 1991, pp. 283-287.
Huang et al., “TCR-Mediated Internalization of Peptide-MHC Complexes Acquired by T Cells”, Science, Oct. 29, 1999, vol. 286, pp. 952-954.
Hwang, et al., “T Cells Can Use Either T Cell Receptor or CD28 Receptors to Absorb and Internalize Cell Surface Molecules Derived from Antigen-presenting Cells”, J. Exp. Med. vol. 191, No. 7, Apr. 3, 2000 pp. 1137-1148.
Jackson et al, “Empty and Peptide-Containing Conformers of Class I Major Histocompatibility Complex Molecules Expressed inDrosophila MelanogasterCells”, Proceedings of the National Academy of Sciences USA 89: pp. 12117-12121 Dec. 1992.
Kawakami, Y. et al, “Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression”, The American Association of Immunologists, Jan. 1995, pp. 3961-3968.
Lanzavecchia, A., “License to Kill”, Nature, vol. 393:4 Jun. 1998 pp. 413-414.
Latouche, et al., “Induction of Human Cytotoxic T Lymphocytes by Artificial Antigen-Presenting Cells,” Nature Biotech (2000) 18: pp. 405-409.
Lustgarten, J. et al., “Specific elimination of IgE Production Using T Cell Lines Expressing Chimeric T cell Receptor Genes”, Eur. J. Immunol., 1995, 25, pp. 2985-2991.
Luxembourg, Alain, et al., “Biomagnetic Isolation of Antigen-Specific CD8+T Cells Usable in Immunotherapy”, Nature Biotechnology, vol. 16, Mar. 1998, pp. 281-285.
Mackensen et al., “Phase I Study in Melanoma Patients of a Vaccine with Peptide-Pulsed Dendritic Cells Generated in Vitro From CD34+Hematopoletic Progenitor Cells”, Int. J. Cancer: 86, pp. 385-392 (2000).
Matsumara, et al., “In Vitro Peptide Binding to Soluble Empty Class I Major Histocompatibility Complex Molecules Isolated from TransfectedDrosophila melanogasterCells”, J. of Biological Chemistry, 1992, vol. 267, No. 33, pp. 23589-23595.
Miescher, et al, “Preferential Clonogenic Deficit of CD8-Positive T-Lymphocytes Infiltrating Human Solid Tumors”, Cancer Research 48, pp. 6992-6998, Dec. 15, 1988.
Mitchell, et al., Phase I Trial of Adoptive Immunotherapy with Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope, J. Clinical Oncology, vol. 20, No. 4 (Feb. 15) 2002: pp. 1075-1086.
Monks, et al., “Three-Dimensional Segregation of Supramolecular Activation Clusters in T Cells”, Nature, vol. 395, Sep. 3, 1998: pp. 82-86.
Montagna, et al., “Dendritic Cells Pulsed with Leukemia Blasts Elicit in Vitro Potent Anti-Leukemia Cytotoxic T-Cell Response in Patients given Allogeneic Bone Marrow Transplantation and in their Donors”, Blood, 2000, vol. 96: 175a, Poster Abstract #753.
Montagna, et al., Ex Vivo Priming for
Cai Zeling
DeGraw Juli
Jackson Michael R.
Kong Yan
Peterson Per A.
Belyavskyi Michail
Ortho-McNeil Pharmaceutical Corp.
LandOfFree
Ex-vivo priming for generating cytotoxic T lymphocytes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ex-vivo priming for generating cytotoxic T lymphocytes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ex-vivo priming for generating cytotoxic T lymphocytes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252974